Mario suggested using FDA to determine viability for Gwen's doxorubicin experiments. I've observed during complement based cytotoxicity experiments lymphocytes exhibiting near-normal light scatter, disrupted cellular membranes (PI+), and active cytoplasmic enzyme activity (FDA+). Depending on timing, FDA may not be an ideal indicator for viability. However, I have no other suggestions.
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:50:01 EST